@FiercePharma: WSJ: J&J's multibillion-$$ Risperdal settlement snags on breast side effects. $JNJ worried a/b civil suits. Article | Follow @FiercePharma
@EricPFierce: Pharma M&A way up in Q1 2013 compared to a year ago. Value up more than 500%. Feature | Follow @EricPFierce
> Lundbeck has launched Selincro, its drug for alcohol dependence, in the U.K. Story
> India's National Pharmaceutical Pricing Authority (NPPA) has denied price boosts to Sanofi ($SNY), Novartis ($NVS), and Allergan ($AGN) for some of their imported drugs. Story
> Cipla and three other Indian drug companies are being investigated for their parts in an alleged deal that gave them preferential treatment for drug contracts. Story
> Pain Therapeutics, said Pfizer ($PFE), is unsure if it wants to go forward with regulatory approval for the painkiller Remoxy. Report
> Ralph Neas, CEO of the Generic Pharmaceutical Association (GPhA), used a letter in The New York Times to take a swipe at state laws restricting biosimilars. Letter
@FierceMedDev: Boston Scientific: Watchman beats warfarin in follow-up. Article | Follow @FierceMedDev
@MarkHFierce: Nanostim's leadless pacer has had some success in early human trials. Future buyer St. Jude Medical must be pleased. Story | Follow @MarkHFierce
@DamianFierce: St. Jude: Independent analysis says Durata leads are safe, reliable. Report | Follow @DamianFierce
> CareFusion's revenue slips 2%. Item
> U.K. pair challenges earlier finding that substandard PIP breast implants were safe. Report
> Quest settles New York case over illegal hiring practices. Story
Biotech News
@FierceBiotech: Special report: Which Big Biotechs are hitting the gas pedal on R&D spending? Feature | Follow @FierceBiotech
@JohnCFierce: Looks like Takeda management maybe in for more changes.The numbers are awful. Report | Follow @JohnCFierce
@RyanMFierce: My story on how industry legend Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups. Article | Follow @RyanMFierce
> Eli Lilly jettisons cancer contender after another Phase III failure. Story
> Biotech VC firm Frazier Healthcare closes in on $300M fund. More
> Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup. News
And Finally... Federal authorities in Puerto Rico have arrested a Pfizer executive that they say sent sexually explicit photos to a 16-year-old boy. Story